title: [Expression of p53 in gallbladder carcinoma and in dysplastic and metaplastic lesions of the surrounding mucosa].
abstract: We studied the expression of p53 in 80 gallbladder carcinomas, 43 peritumoral mucosae, 5 adenomas and 20 mucosae of non tumoral gallbladders. Gallbladder cancers were classified according to WHO criteria. We found p53 overexpression in 51 out of the 80 gallbladder cancers (64%). p53 expression was variable in different histologic subtypes: 100% of intestinal type, 66% of papillary type, 83% of adenosquamous carcinomas and 66% of giant cells cancers showed immunoreactive cells. In well and moderately differentiated conventional gallbladder adenocarcinomas we found 60% of positive cases, while, among poorly differentiated conventional cancers, 83% were immunoreactive. All mucinous adenocarcinomas were p53-negative. In peritumoral dysplastic mucosae, p53 was expressed in 23 out 38 cases (60%), 22 (96%) of which were associated to a p53-positive adenocarcinoma. On the contrary, only 5 of the 15 p53-negative dysplastic lesions (33%) were associated to an p53-immunoreactive adenocarcinoma. Metaplastic lesions, of gastric and intestinal type, and adenomas were completely p53-negative. In conclusion, our data suggest that p53 expression is an early event, frequently involved in gallbladder carcinogenesis, and related to different histologic subtypes of gallbladder adenocarcinomas.
authors.affiliation: Dipartimento di Scienze Cliniche e Biologiche, Università dell'Insubria, Varese.
authors.forename: P
authors.initials: P
authors.lastname: Billo
authors.forename: C
authors.initials: C
authors.lastname: Marchegiani
authors.forename: C
authors.initials: C
authors.lastname: Capella
authors.forename: F
authors.initials: F
authors.lastname: Sessa
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000737:chemistry / Q000235:genetics / Q000473:pathology; D000236:Adenoma / Q000737:chemistry / Q000235:genetics / Q000473:pathology; D002277:Carcinoma / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D018196:Carcinoma, Adenosquamous / Q000737:chemistry / Q000235:genetics / Q000473:pathology; D002291:Carcinoma, Papillary / Q000737:chemistry / Q000235:genetics / Q000473:pathology; D004848:Epithelium / Q000737:chemistry / Q000473:pathology; D005704:Gallbladder / Q000737:chemistry* / Q000473:pathology; D005705:Gallbladder Diseases / Q000378:metabolism / Q000473:pathology; D005706:Gallbladder Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology; D016158:Genes, p53; D006801:Humans; D007124:Immunoenzyme Techniques; D008679:Metaplasia; D009092:Mucous Membrane / Q000737:chemistry / Q000473:pathology; D009363:Neoplasm Proteins / Q000032:analysis*; D011230:Precancerous Conditions / Q000378:metabolism / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
chemical_list: D009363:Neoplasm Proteins; D016159:Tumor Suppressor Protein p53